scispace - formally typeset
F

Francesco Petrella

Researcher at European Institute of Oncology

Publications -  214
Citations -  3297

Francesco Petrella is an academic researcher from European Institute of Oncology. The author has contributed to research in topics: Lung cancer & Pneumonectomy. The author has an hindex of 26, co-authored 189 publications receiving 2404 citations. Previous affiliations of Francesco Petrella include University of Bologna & University of Milan.

Papers
More filters
Journal ArticleDOI

Non-small-cell lung cancer

TL;DR: This Primer focuses on non-small-cell lung cancer, a heterogeneous class of tumours, which represents approximately 85% of all new lung cancer diagnoses and has a very poor prognosis.
Journal ArticleDOI

CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer

TL;DR: Air bronchogram, pleural retraction, small size relate to EGFR mutation in NSCLC, and ALK rearrangements were associated with age and pleural effusion, and KRAS mutation was associated with round shape, nodules in non-tumour lobes, and smoking.
Journal ArticleDOI

A 10-year single-center experience on 708 lung metastasectomies: the evidence of the "international registry of lung metastases".

TL;DR: The validity of the International Registry of Lung Metastases classification system in patients who underwent curative lung metastasectomy in a single center was confirmed and completeness of surgery, histology, and DFI ≥36 months as independent prognostic factors were confirmed.
Journal ArticleDOI

Robotic Anatomic Segmentectomy of the Lung: Technical Aspects and Initial Results

TL;DR: Robotic anatomic lung segmentectomy is feasible and safe procedure and by improving ergonomic, surgeon view and precise movements, may make minimally invasive segmentectomy easier to adopt and perform.
Journal ArticleDOI

Volatile signature for the early diagnosis of lung cancer

TL;DR: Results show that this electronic nose can discriminate the exhaled breath of the lung cancer patients from those of the healthy controls, and the largest sensitivity is observed for the subgroup of patients with a lung cancer at stage I.